Company: Dr. Reddy's Laboratories Ltd. Category: Company News

The Nifty Pharma index dropped 3% led by losses seen in Dr Reddys, Glenmark and Sun Pharma.
Aug. 14, 2019, 9:37 a.m.

No Form 483 was issued at the end of the inspection.
Aug. 9, 2019, 12:05 p.m.

Steady improvement in the US and India market growth keeps analysts positive
July 30, 2019, 9:26 p.m.

Earnings were driven by one-off gains
July 30, 2019, 1:35 p.m.

The company's board approved the merger of Dr. Reddy's Holdings Limited with itself.
July 30, 2019, 10:29 a.m.

A combination of factors, including an 8% growth in global generics business and the other operating income drove the growth in net profit of Dr Reddy's during the first quarter ended June, 2019
July 29, 2019, 9:05 p.m.

The company had reported a net profit of ₹456.1 crore in the corresponding period of 2018-19.Revenues during the period rose to ₹3,843.5 crore as compared with ₹3,720.7 crore in the year-ago period
July 29, 2019, 5:40 p.m.

Consolidated revenue is expected to witness growth of 7.4% yoy on new launches in US (gSuboxone and gPropofol), growth in India and growth in CIS markets.
July 29, 2019, 9:25 a.m.

The product is a generic version of Takeda Pharmaceutical Company's Rozerem tablets in the same strength
July 23, 2019, 4:15 p.m.

The Rozerem brand had US sales of ~$91.3mn MAT for the most recent twelve months ending in May 2019 according to IQVIA Health.
July 23, 2019, 3:36 p.m.